drugset / Trial / NCT00901303
Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to determine the progression-free survival \[PFS\] at 36 months for patients with Hodgkin lymphoma who achieve a complete metabolic response as demonstrated by a negative fluorodeoxyglucose (FDG)-PET scan after one cycle of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) who undergo abbreviated ABVD chemotherapy (3 cycles).
Timeline
- Start
- 2008-10
- Primary completion
- 2010-06
- Completion
- 2011-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bleomycin | Unknown | 10 unknown | — |
| Subject | Dacarbazine | Small molecule | 375 unknown | — |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | — |
| Subject | Vinblastine | Small molecule | 6 mg/m2 | — |